共 50 条
- [45] Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial JOURNAL OF CROHNS & COLITIS, 2013, 7 (01): : 34 - 43
- [47] Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1031 - S1032
- [50] Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 194 - 202